Peytant Solutions, Inc., headed by CEO John Schorgl, is committed to improving quality of life for patients worldwide by utilizing regenerative biomaterials to provide transformational solutions for luminal diseases. The first product in the platform is the AMStent™ System. Intended for treatment of malignant airway strictures, the AMStent System covers stent technology with human amnion tissue. Unlike synthetic coverings, which elicit an immune reaction, amniotic tissue is a natural material that provides a scaffold to support attachment of native epithelial cells. Amniotic tissue has an extensive clinical history, is well-tolerated, and exhibits minimal immunogenicity. AMStent will provide end-of-life palliative relief for patients who need it most.
A new “home” with a clean room, and securing grant monies to conduct sterilization and biocompatibility validation testing, brings Peytant Solutions two big steps closer to 510k application submission. “It was tough to leave the close-knit ‘garage’ environment at UEL,” said Schorgl. “UEL provided a supportive launching pad, and we’ll always be grateful for the experience and opportunity they afforded us.” The sentiment flows both ways, “While we love to see our tenants outgrow our UEL innovation community, well-positioned for the next phase, it’s a little bittersweet to see Peytant go. We wish them great success,” said Lynne Osterman, UEL Executive Director.
Driving commercialization of a predicate device with novel technology in the $13.3B global stent market requires funding. Peytant Solutions is currently raising $4M to support FDA clearance. The company is off to a great start after being awarded a 2017 Biobusiness Grant from Regenerative Medicine Minnesota.